Digital Support Program Triples Muscle Preservation During GLP-1 Weight Loss
A 12-week Omada Health study shows coaching and strength training dramatically improve fat loss and muscle retention alongside GLP-1 drugs.
Summary
A new 12-week study from Omada Health found that adults on GLP-1 weight loss medications who also used a digital support program lost 1.8 times more total weight than those without it. More importantly, they reduced body fat percentage twice as much and increased muscle mass percentage nearly threefold. The program combined health coaching, strength-focused exercise, and digital tools. Participants also reported better mental health, physical functioning, and confidence in managing their weight. The findings challenge the idea that the number on the scale is enough — highlighting that preserving muscle while losing fat is critical for long-term metabolic health, mobility, and aging resilience.
Detailed Summary
GLP-1 medications like semaglutide have rapidly transformed weight loss treatment, but a growing concern shadows their success: rapid weight loss often strips away lean muscle mass alongside fat. Muscle is metabolically essential — it regulates blood sugar, supports mobility, and buffers against age-related physical decline. Losing it while losing weight can leave the body weaker and more fragile, not healthier.
Omada Health's new 12-week study directly addresses this tradeoff. Adults with obesity who had recently started GLP-1 medications were divided into two groups — one using Omada's GLP-1 Care Track program, the other receiving no additional support. The Care Track combined health coaching, strength-focused exercise guidance, and digital monitoring tools designed to optimize the composition of weight loss, not just its quantity.
The results were striking. Omada program participants lost 1.8 times more total weight. More significantly, they reduced body fat percentage by twice as much and increased their muscle mass percentage by nearly threefold compared to the control group. These body composition shifts matter far more for long-term health than scale weight alone, particularly for aging adults where muscle loss accelerates metabolic and functional decline.
Beyond physical metrics, participants in the Omada group reported meaningful improvements in mental health, physical functioning, and self-efficacy around weight management. Confidence in sustaining healthy behaviors is often the deciding factor in whether health gains persist or reverse over time.
For employers, insurers, and clinicians investing in GLP-1 therapies, this study reframes what a successful outcome looks like. However, the study is industry-sponsored and short in duration at just 12 weeks. Independent replication over longer timeframes is needed before firm conclusions can be drawn. Still, the core message is actionable: pairing GLP-1 medications with structured strength training and behavioral coaching appears to meaningfully improve the quality of weight loss.
Key Findings
- GLP-1 users in the Omada program lost 1.8x more total weight than those without digital support.
- Body fat percentage reduced twice as much in the coached group versus controls over 12 weeks.
- Muscle mass percentage increased nearly threefold in participants using the Omada Care Track program.
- Participants reported improved mental health, physical functioning, and weight management confidence.
- Structured strength training alongside GLP-1 therapy may prevent the muscle loss common with rapid weight loss.
Methodology
This is a news report summarizing a 12-week industry-sponsored study by Omada Health, a digital therapeutics company with a commercial interest in the findings. The study compared GLP-1 users with and without Omada's Care Track program but has not yet been described as peer-reviewed or published in a named journal, limiting independent verification.
Study Limitations
The study is industry-sponsored by Omada Health, introducing potential bias in design and reporting. At only 12 weeks, long-term durability of muscle preservation and fat loss outcomes remains unknown. The article does not confirm peer review or journal publication, so primary source verification is strongly recommended.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.